Clinical trials: Active Population
Psoriasis Vulgaris
A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream
This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating efficacy, safety and convenience of the MC2-01 cream.
- Trial name
- NCT03308799
- Testing
- MC2-01 cream, Cal/BDP combination, Cream vehicle
- Where
- 3 sites in United States
- Volunteers
- 794 people
- Sponsor
- MC2 Therapeutics
Crohn's Disease
One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease
The primary objective is to determine the efficacy of rifaximin DR also referred to as Extended Intestinal Release (EIR) tablets vs.
- Trial name
- NCT02240121
- Testing
- Rifaximin EIR
- Where
- 72 sites in United States
- Volunteers
- 80 people
- Sponsor
- Bausch Health Americas, Inc.
Arthritis, Rheumatoid
A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)
The purpose of this study is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of rheumatoid arthritis (RA) and inhibition of radiographic progression in patients with active RA who are…
- Trial name
- NCT01604343
- Testing
- Sirukumab
- Where
- 156 sites in United States, Bulgaria and 16 more
- Volunteers
- 1,670 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change.
- Trial name
- LixiLan-G (NCT02787551)
- Testing
- Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide
- Where
- 124 sites in United States, Canada and 7 more
- Volunteers
- 514 people
- Sponsor
- Sanofi
Macular Edema
Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)
To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different intravitreal (IVT) treatment regimens to participants with DME pretreated with 2 mg aflibercept every 8 weeks after 5 initial monthly injections…
- Trial name
- VIOLET (NCT02818998)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- 64 sites in Austria, Canada and 12 more
- Volunteers
- 463 people
- Sponsor
- Bayer
Type 2 Diabetes Mellitus
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
Primary Objective: To demonstrate the superiority of Soliqua 100/33 versus Lantus in the hemoglobin A1c (HbA1c) change within the overall population.
- Trial name
- LixiLan-D (NCT03434119)
- Testing
- Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy
- Where
- 85 sites in United States
- Volunteers
- 241 people
- Sponsor
- Sanofi
Hypertension
Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure
Randomized, double-blind, parallel group, multicenter study of subjects with Stage 1 or 2 essential hypertension who are not at target blood pressure (<140/90mmHg) at Baseline.
- Trial name
- NCT00624065
- Testing
- carvedilol controlled release/lisinopril
- Where
- 76 sites in United States
- Volunteers
- 348 people
- Sponsor
- GlaxoSmithKline
Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT03118765
- Testing
- GSP304 (tiotropium bromide) Inhalation Solution, Spiriva® Respimat® inhalation spray
- Where
- 25 sites in United States
- Volunteers
- 155 people
- Sponsor
- Glenmark Specialty S.A.
Acne Vulgaris
Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels
The purpose of this study is to compare the efficacy and safety profiles of Perrigo Israel Pharmaceuticals, Ltd. Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel and Benzaclin® Topical Gel (Clindamycin- Benzoyl Peroxide Gel).
- Trial name
- NCT01138514
- Testing
- Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo), Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)
- Volunteers
- 1,555 people
- Sponsor
- Padagis LLC
Type 2 Diabetes
Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment.
- Trial name
- NCT00660907
- Testing
- dapagliflozin, glipizide, metformin hydrochloride
- Where
- 76 sites in Argentina, France and 8 more
- Volunteers
- 1,217 people
- Sponsor
- AstraZeneca
Arthritis, Gouty
Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout
This is an exploratory proof-of-concept study to evaluate the safety and efficacy of canakinumab (ACZ885) for inflammation and pain associated with acute gouty arthritis.
- Trial name
- NCT00663169
- Testing
- canakinumab, dexamethasone
- Where
- 4 sites in United States, Switzerland and 1 more
- Volunteers
- 6 people
- Sponsor
- Novartis
Major Depressive Disorder
Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries
This study will be conducted with the aim of investigating the efficacy, safety and tolerability of 10 mg/day Vortioxetine in Asian patients compared to an approved active comparator (venlafaxine extended release 150 mg/day).
- Trial name
- NCT01571453
- Testing
- Vortioxetine (Lu AA21004), Venlafaxine extended release
- Volunteers
- 437 people
- Sponsor
- H. Lundbeck A/S
Acute Otitis Externa
Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Otic Solution in the Treatment of Acute Otitis Externa
This is a phase Ⅲ, multicenter, randomized, evaluator-blinded, parallel-group, active-controlled study to assess the efficacy and safety of ciprofloxacin 0.3% plus fluocinolone acetonide 0.025% otic solution vs ciprofloxacin 0.3%…
- Trial name
- NCT04636957
- Testing
- Ciprofloxacin-Fluocinolone Acetonide, 0.3%-0.025% Otic Solution, Ciprofloxacin 0.3% solution
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Lee's Pharmaceutical Limited
Treatment Outcome
Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.
- Trial name
- NCT01364649
- Testing
- Vortioxetine, Escitalopram
- Where
- 62 sites in United States, Canada
- Volunteers
- 447 people
- Sponsor
- Takeda
Type 1 Diabetes Mellitus
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
Primary Objective: To demonstrate that morning injection of Toujeo (HOE901-U300) compared to Lantus provides better glycemic control evaluated by Continuous Glucose Monitoring (CGM) in adult participants with type 1 diabetes…
- Trial name
- NCT02688933
- Testing
- HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
- Where
- 100 sites in United States, Puerto Rico
- Volunteers
- 638 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)
This randomized, parallel-group, open-label study will evaluate the effect of Actemra (tocilizumab) on vaccination in patients with active rheumatoid arthritis who have an inadequate response to methotrexate and who have had an…
- Trial name
- NCT01163747
- Testing
- tocilizumab, methotrexate, 23-Valent Pneumococcal Polysaccharide Vaccine
- Where
- 47 sites in United States
- Volunteers
- 91 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
The purpose of this study is to evaluate the efficacy and safety of namilumab in combination with existing methotrexate (MTX) therapy over 24 weeks in participants with moderate to severe early rheumatoid arthritis (RA)…
- Trial name
- TELLUS (NCT02393378)
- Testing
- Namilumab, Adalimumab, Methotrexate
- Where
- 13 sites in Czechia, Estonia and 3 more
- Volunteers
- 7 people
- Sponsor
- Takeda
Arthritis, Rheumatoid
A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis
The purpose of this study is to evaluate the efficacy and safety of nipocalimab versus placebo in participants with moderate to severe active rheumatoid arthritis (RA).
- Trial name
- NCT04991753
- Testing
- Nipocalimab
- Where
- 28 sites in United States, Germany and 3 more
- Volunteers
- 53 people
- Sponsor
- Janssen Research & Development, LLC
Moderate to Severe Chronic Pain
A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.
The main purpose of this study is to evaluate the effect of NKTR-181 on brain activity in healthy, non-physically dependent recreational opioid users. This study will last about 88 days for each participant.
- Trial name
- NCT03802227
- Testing
- NKTR-181, Oxycodone IR
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Nektar Therapeutics
Healthy
Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin
To evaluate the photosensitivity potential of BI 730357
- Trial name
- NCT04147260
- Testing
- BI 730357, Ciprofloxacin
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim